Perspective Therapeutics, Inc.CATXNYSE
Loading
R&D Expense Growth TrendStable
Percentile Rank93
3Y CAGR+409.2%
5Y CAGR+30.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+409.2%/yr
Annual compound
5Y CAGR
+30.8%/yr
Recent acceleration
Percentile
P93
Near historical high
vs 5Y Ago
3.8x
Strong expansion
Streak
1 yr
Consecutive growthStable
| Period | Value |
|---|---|
| 2025 | 102.26% |
| 2024 | 95.38% |
| 2023 | 719.02% |
| 2022 | 0.77% |
| 2021 | 80.94% |
| 2020 | 26.73% |
| 2019 | -23.61% |
| 2018 | -15.58% |
| 2017 | 80.93% |
| 2016 | 82.75% |